Add Liposana® to Your Practice
Give patients with plantar fat pad atrophy a structural cushion made from real human tissue. Liposana® is offered exclusively through AIMx Podiatry.
What Is Liposana®?
A human adipose tissue allograft for patients with plantar fat pad atrophy. It supplements thinning padding with real fat tissue.
Real human fat tissue
Liposana® is made from donated human adipose tissue. It keeps the natural structure of fat, including intact, lipid-filled fat cells, so it cushions like the fat pad it supplements.
Regulated as a 361 HCT/P
Regulated by the FDA as a 361 HCT/P for homologous use. Donors are screened and tissue is recovered and processed under FDA and AATB standards.
Placed in office
Placed in the office under local anesthetic in a single visit. No harvesting from the patient is needed.
Native Adipose vs. Other Options
How Liposana® compares with other options patients may already know about.
| Attribute | Liposana® | Synthetic and Dermal Fillers | Steroid Injections |
|---|---|---|---|
| What it is | Human adipose tissue allograft that retains its native tissue structure | Synthetic materials or gels, including silicone and hyaluronic acid | Corticosteroid medications used to reduce inflammation |
| Adds cushioning to the fat pad | Provides natural adipose tissue volume and cushioning | Adds volume but does not replicate native adipose tissue structure | Reduces inflammation but does not restore lost cushioning |
| How it works over time | Supplements existing adipose tissue and gradually remodels and integrates with the patient's own tissue over time | Provides temporary or lasting volume, depending on the material; migration and other complications may occur | Does not replace lost adipose tissue; repeated injections may contribute to fat pad atrophy |
| FDA regulatory status | Regulated as a Section 361 HCT/P for homologous use | Not FDA-approved for restoring plantar fat pad cushioning | FDA-approved medications, but not specifically approved to restore fat pad cushioning |
Sources: Schoenhaus Gold et al. 2025; Regulski et al. 2024, and the literature they cite.
Published Research
Read the peer reviewed publications on Liposana®.
Diabetic neuropathic patient with a pre-ulcerative plantar lesion from fat pad atrophy. No re-ulceration or adverse events out to 9 months.
Retrospective case series, 9 patients (10 feet) with metatarsalgia from fat pad atrophy, 1.5 mL each. At 12 weeks, 9 of 10 feet gained fat pad thickness on ultrasound (mean 0.21 cm, 65%), and FADI rose from 66.0 to 84.2. No adverse events were reported.
Laboratory and 12 week nude mouse study of tissue structure, immunogenicity, and graft fate. Supports host-mediated tissue replacement as the mechanism behind durable volume.
Why Practices Offer Liposana®
Cash pay
No insurance billing to manage. Patients pay the practice directly.
Patients looking for you
Practices that choose to be listed appear in the Find a Provider search on this site, where patients search by zip code.
Provider Support
Support with marketing, patient education, and more.
Durable cushion
Patients have reported cushioning lasting 24 months or more.
Let's Talk
Share your details and AIMx Podiatry will follow up. Prefer to call? Reach us at 737-377-3655.
This form is for healthcare providers. Patients, please use Find a Provider on our home page.